Wu Jun-Yi, Huang Li-Ming, Bai Yan-Nan, Wu Jia-Yi, Wei Yong-Gang, Zhang Zhi-Bo, Yan Mao-Lin
Department of Hepatobiliary Surgery, the Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
Front Oncol. 2021 Nov 5;11:723455. doi: 10.3389/fonc.2021.723455. eCollection 2021.
There are still challenging problems in diagnosis of hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) before operation. This study aimed to analyze the imaging features of HCC with B1-B3 BDTT.
The clinicopathological data and imaging findings of 30 HCC patients with B1-B3 BDTT from three high-volume institutions were retrospectively reviewed. A total of 631 patients without BDTT who were randomly collected from each of the enrolled centers were recorded as the control group to analyze the differences in clinicopathological characteristics and imaging features between the two groups. A total of 453 HCC patients who underwent surgical treatment in the three institutions from January 2020 to December 2020 were collected for a blinded reading test as the validation group.
HCC patients with B1-B3 BDTT had more advanced tumor stages and adverse clinicopathological features. HCC lesions were detected in all patients, and intrahepatic bile duct dilation was observed in 28 (93.3%) patients with B1-B3 BDTT and 9 (1.43%) patients in HCC without BDTT. The intrahepatic bile duct dilation showed no enhancement at hepatic arterial phase (HAP) and no progressively delayed enhancement at portal venous phase (PVP), but it was more obvious at PVP on CT. In the reports of the 30 HCC patients with B1-B3 BDTT generated for the image when the scan was done, BDTT was observed in all 13 B3 patients and 3 of 12 B2 patients, but none of the 5 B1 patients. Fourteen patients were misdiagnosed before surgery. However, when using intrahepatic bile duct dilation in HCC patients as a potential biomarker for BDTT diagnosis, the sensitivity and specificity for BDTT diagnosis were 93.33% and 98.57%, respectively. The blinded reading test showed that intrahepatic bile duct dilation in CT and MRI scans could be for separating HCC patients with B1-B3 BDTT from HCC patients without BDTT.
The HCC lesions and intrahepatic bile duct dilation on CT or MRI scans are imaging features of HCC with BDTT, which might facilitate the early diagnosis of B1-B3 BDTT.
肝细胞癌(HCC)合并胆管癌栓(BDTT)术前诊断仍存在挑战性问题。本研究旨在分析B1 - B3级BDTT的HCC的影像学特征。
回顾性分析来自三家大型机构的30例B1 - B3级BDTT的HCC患者的临床病理资料和影像学表现。从每个入组中心随机收集631例无BDTT的患者作为对照组,分析两组临床病理特征和影像学特征的差异。收集2020年1月至2020年12月在这三家机构接受手术治疗的453例HCC患者进行盲法阅片测试作为验证组。
B1 - B3级BDTT的HCC患者肿瘤分期更晚,临床病理特征更差。所有患者均检测到HCC病灶,28例(93.3%)B1 - B3级BDTT患者及9例(1.43%)无BDTT的HCC患者观察到肝内胆管扩张。肝内胆管扩张在肝动脉期(HAP)无强化,门静脉期(PVP)无渐进性延迟强化,但在CT上PVP时更明显。在为扫描图像生成的30例B1 - B3级BDTT的HCC患者报告中,13例B3患者及12例B2患者中的3例观察到BDTT,而5例B1患者均未观察到。14例患者术前误诊。然而,将HCC患者肝内胆管扩张作为BDTT诊断的潜在生物标志物时,BDTT诊断的敏感性和特异性分别为93.33%和98.57%。盲法阅片测试表明,CT和MRI扫描中的肝内胆管扩张可用于区分B1 - B3级BDTT的HCC患者和无BDTT的HCC患者。
CT或MRI扫描上的HCC病灶及肝内胆管扩张是BDTT的HCC的影像学特征,这可能有助于B1 - B3级BDTT的早期诊断。